Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 10/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749131 | 1.00 | MAPT (0.47) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL23714913 | 0.88 | LMNA (0.47) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL19889341 | 0.85 | LMNA (0.47) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL30697940 | 0.83 | BACE1 (0.50) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL17802125 | 0.80 | MAPT (0.46) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL29616597 | 0.80 | RARA (0.48) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL2599701 | 0.80 | RARA (0.48) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL30353231 | 0.78 | AKR1B1 (0.55) | MAPTBACE1AKR1B10AKR1A1AKR1B1 | |
| SCHEMBL30353277 | 0.78 | AKR1B1 (0.35) | MAPTAKR1B10AKR1A1AKR1B1 | |
| SCHEMBL30353228 | 0.78 | CYP3A4 (0.42) | MAPTMAOBAKR1B10AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907389-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-08-16 | — | — | CN | disclosed |